

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM775946

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	First Amendment to IP Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
KALA PHARMACEUTICALS, INC.		12/19/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	OXFORD FINANCE LLC		
<b>Street Address:</b>	115 South Union Street		
<b>Internal Address:</b>	Suite 300		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4585580	KALA	
<b>Registration Number:</b>	5401810	KALA	
<b>Serial Number:</b>	90749282	ZUDREYA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Email:</b>	bethany.stokes@gtlaw.com		
<b>Correspondent Name:</b>	Bethany A. Stokes		
<b>Address Line 1:</b>	Greenberg Traurig, LLP		
<b>Address Line 2:</b>	One International Place, Suite 2000		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02110		
<b>ATTORNEY DOCKET NUMBER:</b>	138179.019300		
<b>NAME OF SUBMITTER:</b>	Bethany A. Stokes		
<b>SIGNATURE:</b>	/Bethany A. Stokes/		
<b>DATE SIGNED:</b>	12/22/2022		
<b>Total Attachments: 30</b>			
source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page1.tif			

CH \$90.00 4585580



## FIRST AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

This First Amendment to Intellectual Property Security (“**First Amendment**”) is entered into as of December 19, 2022 (**First Amendment Date**) by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“**Oxford**”) as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders described in that certain Loan and Security Agreement, dated as of May 4, 2021 (as amended, modified or supplemented from time to time, the “**Loan Agreement**”) from time to time, including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**), and KALA PHARMACEUTICALS, INC., a Delaware corporation with an address located at 1167 Massachusetts Ave., Arlington, MA 02476 (“**Grantor**”). Collateral Agent, Grantor are sometimes referred to herein collectively as the “**Parties**,” and individually as a “**Party**.”

WHEREAS, the Parties and Combangio, Inc. have entered into the Loan Agreement pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms thereof;

WHEREAS, in connection with the Loan Agreement, on May 4, 2021, the Parties entered into that certain Intellectual Property Security Agreement (“**IPSA**”) pursuant to which Grantor granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in the Intellectual Property Collateral;

WHEREAS, the IPSA was recorded with the Patent Division and Trademark Division of the United States Patent and Trademark Office on May 6, 2021, at Reel/Frame 056168/0602 and Reel/Frame 007282/0798, respectively, to evidence the security interest granted under the IPSA;

WHEREAS, the Parties entered into that certain Release of Security Interest in Certain Intellectual Property on July 8, 2022 (the “**Partial Release**”) pursuant to which Collateral Agent agreed to release, discharge, terminate and cancel its security interest in certain Intellectual Property Collateral;

WHEREAS, the Partial Release was recorded with the Patent Division and Trademark Division of the United States Patent and Trademark Office on July 8, 2022, at Reel/Frame 060614/0713 and Reel/Frame 007773/0895, respectively, to evidence the release granted under the Partial Release; and

WHEREAS, the Parties desire to amend certain provisions of the IPSA as provided herein and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

1. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Loan Agreement.
2. Exhibit B of the IPSA is hereby amended and restated in its entirety as set forth in Exhibit A attached hereto.
3. Exhibit C of the IPSA is hereby amended and restated in its entirety as set forth in Exhibit B attached hereto.

4. To induce Collateral Agent and Lenders to enter into this First Amendment, Grantor hereby represents and warrants to Collateral Agent and Lenders as follows that set forth on Exhibit A and Exhibit B is a complete and current list of Grantor's Patents and Trademarks, respectively, on the date hereof.

5. Except as expressly set forth herein, the IPSA shall continue in full force and effect without alteration or amendment. This First Amendment is, and shall be considered for all purposes, a Loan Document and this First Amendment together with the other Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

6. This First Amendment shall be deemed effective as of the First Amendment Date upon the due execution and delivery to Collateral Agent of this First Amendment by each Party hereto.

7. This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

8. This First Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.

*[Remainder of page left intentionally blank]*

IN WITNESS WHEREOF, the parties have caused this First Amendment to Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

KALA PHARMACEUTICALS, INC.

Address of Grantor:

1167 Massachusetts Ave. Arlington, MA  
02476

Attn: Eric Trachtenberg

By Eric Trachtenberg  
Name: Eric Trachtenberg  
Title: General Counsel and Secretary

**COLLATERAL AGENT:**

OXFORD FINANCE LLC

Address of Collateral Agent:

115 South Union Street  
Suite 300  
Alexandria, VA 22314  
Attn: Legal Department

By \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this First Amendment to Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

KALA PHARMACEUTICALS, INC.

Address of Grantor:

1167 Massachusetts Ave. Arlington, MA  
02476

Attn: Eric Trachtenberg

By \_\_\_\_\_

Name: Eric Trachtenberg

Title: General Counsel and Secretary

**COLLATERAL AGENT:**

OXFORD FINANCE LLC

Address of Collateral Agent:

115 South Union Street  
Suite 300  
Alexandria, VA 22314  
Attn: Legal Department

By \_\_\_\_\_

Name: Colette H. Featherly

Title: Senior Vice President

[Signature Page to First Amendment to IP Security Agreement]

EXHIBIT A

Patents

**PATENT FAMILY: SIL001**

**TITLE(S): TARGETED-IN SITU THERAPEUTIC DELIVERY OF SECRETED FACTORS FROM STEM CELLS FOR TREATMENT OF DAMAGED TISSUE**

*Assignees: Board of Trustees of the Leland Stanford Junior University, The U.S. Government Represented by the Department of Veterans Affairs, The Board of Trustees of the University of Illinois  
In-licensed to Cambargo*

<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
SIL001US	16/614,205 (United States)	15-Nov-2019	Nat'l Phase of SIL001WMO		PENDING
SIL001AU	2018269057 (Australia)	18-May-2018	Nat'l Phase of SIL001WMO		PENDING
SIL001EP	18801734.7 (Europe) [Pub'd as EP3624731 on 25-Mar-2020]	18-May-2018	Nat'l Phase of SIL001WMO		PENDING

**PATENT FAMILY: KP005**

**TITLE(S): THERAPEUTIC COMPOUNDS AND USES THEREOF**

*Assignee: Kale*

<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP005.AUS	14/768,038 (United States) [Pub'd as US2016/0002254 on 07-Jan-2016]	14-Aug-2015 (371 Date)	Nat'l Stage of KP005.AWMO	US 9,695,184 on 4-Jul-2017	GRANTED
KP005.CUS	14/181,095 (United States) [Pub'd as US2014/0235634 on 21-Aug-2014]	14-Feb-2014	US ORD of KP005.A & .BUSPR	US 9,353,122 on 31-May-2016	GRANTED
KP005.CUS2	15/139,099 (United States) [Pub'd as US2016/0235761 on 18-Aug-2016]	26-Apr-2016	CON of KP005.CUS	US 9,827,248 on 28-Nov-2017	GRANTED



KP005: C/US3	15/139,107 (United States) [Pub'd as US2016/0237093 on 18-Aug-2016]	26-Apr-2016	DIV of KP005: C/US	US 9,877,970 on 30-Jan-2018	GRANTED
KP005: C/US4	15/868,894 (United States) [Pub'd as US2018/0133225 on 17-May-2018]	11-Jan-2018	CON of KP005: C/US3	US10,398,703 on 03-Sep-2019	GRANTED
KP005: C/US5	16/522,550 (United States) [Pub'd as US2020/0054644 on 20-Feb-2020]	25-Jul-2019	CON of KP005: C/US4	US10,966,987 on 06-Apr-2021	GRANTED
KP005: C/AU	2014/216,178 (Australia) [Pub'd as AU2014216178 on 03-Sep-2015]	14-Feb-2014	Nat'l Stage of KP005: C/MO	AU2014216178 on 11-Oct-2018	GRANTED
KP005: C/CA	2,900,652 (Canada) [Pub'd as CA2900652 on 21-Aug-2014]	14-Feb-2014	Nat'l Stage of KP005: C/MO	CA2900652 on 05-Apr-2021	GRANTED
KP005: C/EP	14751929.2 (European Patent Office) [Pub'd as EP2956138 on 23-Dec-2015]	14-Feb-2014	Nat'l Stage of KP005: C/MO	EP2956138 on 22-Jun-2022	GRANTED
KP005: C/DE	(Germany)		Validation of KP005: C/EP		GRANTED
KP005: C/FR	(France)		Validation of KP005: C/EP		GRANTED
KP005: C/GB	(United Kingdom)		Validation of KP005: C/EP		GRANTED
KP005: C/JP	2015-558148 (Japan) [Pub'd as JP2016513108 on 12-May-2016]	14-Feb-2014	Nat'l Stage of KP005: C/MO	JP6669499 on 18-Mar-2020	GRANTED

PATENT FAMILY: KP005  
TITLE(S) THERAPEUTIC COMPOUNDS AND USES THEREOF  
Assignee: Kaia

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP006.C/US	14/184,886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	US ORD of KP006.A & .BUSPR	US 9,353,123 on 31-May-2016	GRANTED
KP006.C/US2	15/139,121 (United States) [Pub'd as US2016/0235753 on 18-Aug-2016]	26-Apr-2016	CON of KP006.C/US	US 9,833,453 on 5-Dec-2017	GRANTED
KP006.C/US3	15/139,135 (United States) [Pub'd as US2016/0237094 on 18-Aug-2016]	26-Apr-2016	DIV of KP006.C/US	US 9,861,634 on 9-Jan-2018	GRANTED
KP006.C/US4	15/842,695 (United States) [Pub'd as US2018/0104246 on 19-Apr-2018]	14-Dec-2017	CON of KP006.C/US3	US 10,285,991 on 14-May-2019	GRANTED
KP006.C/US5	16/361,732 (United States) [Pub'd as US2019/0216812 on 18-Jul-2019]	22-Mar-2019	Con of KP006.C/US4	US 10,758,539 on 01-Sep-2020	GRANTED
KP006.C/US6	16/915,508 (United States) [Pub'd as US2020/0323854 on 29-Jun-2020]	29-Jun-2020	CON of KP006.C/US5	US 11,369,611 on 28-Jun-2022	GRANTED
KP006.C/US7	17/747,754 (United States)	05-May-2022			PENDING
KP006.C/AU	2014/219,024 (Australia) [Pub'd as AU2014/219024 on 05- Apr-2018]	20-Feb-2014	Nat'l Stage of KP006.C/MO	AU2014219024 on 19-Jul-2018	GRANTED
KP006.C/AU2	2018/202,312 (Australia) [Pub'd as AU2018202312 on 26- Apr-2018]	20-Feb-2014	DIV of KP006.C/AU	AU2018202312 on 13-Feb-2020	GRANTED
KP006.C/BR	2015-1120139 (Brazil) [Pub'd as BR112015020139 on 18-Jul-2017]	20-Feb-2014	Nat'l Stage of KP006.C/MO		PENDING
KP006.C/CA	2,900,680 (Canada) [Pub'd as CA2900680 on 28-Aug- 2014]	20-Feb-2014	Nat'l Stage of KP006.C/MO	CA2900680 on 10-Aug-2021	GRANTED

KP006.C/CN	2014800212484.8 (China) [Pub'd as CN105189462 on 23-Dec-2015]	20-Feb-2014	Natl' Stage of KP006.C/MO	CN105189462 on 10-Nov-2017	GRANTED
KP006.C/EP	14754329.2 (European Patent Office) [Pub'd as EP2958895 on 30-Dec-2015]	20-Feb-2014	Natl' Stage of KP006.C/MO	EP2958895 on 19-Aug-2020	GRANTED
KP006.C/EP-CH	(Switzerland)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-DE	(Germany)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-ES	(Spain)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-FR	(France)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-GB	(Great Britain)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-IE	(Ireland)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-IT	(Italy)		Valid of KP006.C/EP		GRANTED
KP006.C/EP-NE	(Netherlands)		Valid of KP006.C/EP		GRANTED
KP006.C/EP2	201914132 (European Patent Office) [Pub'd as EP3763710 on 31-Jan-2021]	20-Feb-2014	DIV of KP006.C/EP		PENDING
KP006.C/HK-EP	16105120.4 (Hong Kong) [Pub'd as HK1217191 on 30-Dec-2016]	20-Feb-2014	HK Registration of KP006.C/MO	HK1217191 on 04-May-2021	GRANTED
KP006.C/HK-EP2	42021033402.5 (Hong Kong)	20-Feb-2014	HK Registration of KP006.C/EP2		PENDING

	[Pub'd as HK40043769 on 24-Sep-2021]						
KP006.C/JN	2354/MUMNP/2015 (India) [Pub'd as IN22/2016 on 27-May-2016]	20-Feb-2014	Nat'l Stage of KP006.C/MO	IN378043 on 28-Sep-2021	GRANTED		
KP006.C/J/P2	2018-229512 (Japan) [Pub'd as JP2019055988 on 11-Apr-2019]	20-Feb-2014	DIV of KP006.C/J/P	JP6830943 on 17-Feb-2021	GRANTED		
KP006.C/J/P4	2022-044906 (Japan)	20-Feb-2014	DIV of KP006.C/J/P3		PENDING		
KP006.C/KR	10-2015-7025432 (South Korea) [Pub'd as KR20150119361 on 23-Oct-2015]	20-Feb-2014	Nat'l Stage of KP006.C/MO	KR10-2277833 on 9-July-2021	GRANTED		
KP006.C/MX	MX/a/2015/010829 Mexico [Pub'd as MX2015010829 on 03-Dec-2015]	20-Feb-2014	Nat'l Stage of KP006.C/MO	MX368903 on 20-Feb-2020	GRANTED		

PATENT FAMILY: KP007							
TITLE(S): MEROPENEM DERIVATIVES AND USES THEREOF							
Assignee: <i>Kaia</i>							
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS		
KP007.B/AU	2014/227737 (Australia) [Pub'd as AU2014227737 on 17-May-2018]	15-Mar-2014	Nat'l Stage of KP007.B/MO	AU2014227737 on 30-Aug-2018	GRANTED		
KP007.B/EP	14762750.9 (European Patent Office) [Pub'd as EP2968274 on 20-Jan-2016]	15-Mar-2014	Nat'l Stage of KP007.B/MO	EP2968274 on 16-Oct-2019	GRANTED		
KP007.B/EP-DE	(Germany)	15-Mar-2014	Validation of KP007.B/EP		GRANTED		

KP007.B/EP-FR	(France)	15-Mar-2014	Validation of KP007.B/EP	GRANTED
KP007.B/EP-UK	(Great Britain)	15-Mar-2014	Validation of KP007.B/EP	GRANTED
KP007.B/JP2	2019-023946 (Japan)	15-Mar-2014	Div. of KP007.B/JP	JP6738918 on 22-Jul-2020 GRANTED
KP007.B/US	14777 018 (United States) [Pub'd as US2016/0039823 on 11-Feb-2016]	15-Sep-2015 (371 Date)	Natl Stage of KP007.B/MO	US 9,725,451 on 8-Aug-2017 GRANTED
KP007.B/US2	15650 667 (United States) [Pub'd as US2017/0349590 on 07-Dec-2017]	14-Jul-2017	CON of KP007.B/US	US10,392,388 on 27-Aug-2019 GRANTED
KP007.B/US3	16509 388 (United States) [Pub'd as US2020/0010470 on 09-Jan-2020]	11-Jul-2019	CON of KP007.B/US2	US11,091,487 on 17-Aug-2021 GRANTED

TRADEMARK  
REEL: 007935 FRAME: 0212

PATENT FAMILY: KP008					
TITLE(S) NOVEL COMPOUNDS AND USES THEREOF					
Assignee: <i>Kala</i>					
CUR-REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP008.C/AU	2014/275198 (Australia) [Pub'd as AU2014275198 on 10- Dec-2015]	30-May-2014	Natl Stage of KP008.C/MO	AU2014275198 on 30-Jul-2017	GRANTED
KP008.C/EP	148072325 (European Patent Office) [Pub'd as EP3003314 on 13-Apr- 2016]	30-May-2014	Natl Stage of KP008.C/MO	EP3003314 on 14-May-2019	GRANTED
KP008.C/EP-DE	(Germany)		Validation of KP008.C/EP		GRANTED

KP008: C/EP-FR	(France)			Validation of KP008 C/EP		GRANTED
KP008: C/EP-GB	(Great Britain)			Validation of KP008 C/EP		GRANTED
KP008: C/JP	2016-5177041 (Japan) [Pub'd as JP2016520617 on 14-Jul-2016]	30-May-2014		Nat'l Stage of KP008 C/MO	JP6557654 on 19-Jul-2019	GRANTED
KP008: C/US	14/894,214 (United States) [Pub'd as US2016/0137646 on 19-May-2016]	25-Nov-2015 (371 Date)		Nat'l Stage of KP008 C/MO	US 9,988,386 on 5-Jun-2018	GRANTED
KP008: C/US2	15/970,740 (United States) [Pub'd as US2018/0251467 on 06-Sep-2018]	3-May-2018		CON of KP008 C/US	US 10,351,570 on 16-Jul-2019	GRANTED
KP008: C/US3	16/014,937 (United States) [Pub'd as US2019/0023710 on 24-Jan-2019]	21-Jun-2018		CON of KP008 C/US2	US 10,544,151 on 28-Jan-2020	GRANTED
KP008: C/US4	16/422,606 (United States) [Pub'd as US2020/0157106 on 21-May-2020]	24-May-2019		DIV of KP008 C/US2	US 10,954,244 on 23-Mar-2021	GRANTED

<b>PATENT FAMILY: KP009</b> <b>TITLE(S): UREA DERIVATIVES AND USES THEREOF</b> <i>Assignee: Kala</i>						
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS	

KP009; C/US	14/301,653 (United States) [Pub'd as US 2015/0072986 on 12-Mar-2015]	11-Jun-2014	US ORD of KP009, A & .B/USPR	US 9,212,145 on 15-Dec-2015	GRANTED
KP009; C/US2	14/939,727 (United States) [Pub'd as US 2016/0060264 on 03-Mar-2016]	12-Nov-2015	DIV of KP009; C/US	US 9,560,421 on 28-Feb-2017	GRANTED
KP009; C/US3	15/411,485 (United States) [Pub'd as US2017/0129876 on 11-May-2017]	20-Jan-2017	DIV of KP009; C/US2	US 9,802,922 on 31-Oct-2017	GRANTED
KP009; C/US4	15/782,696 (United States) [Pub'd as US2018/0037572 on 18- Feb-2018]	12-Oct-2017	CON of KP009; C/US3	US 10,059,692 on 28-Aug-2018	GRANTED
KP009; C/US5	15/782,743 (United States) [Pub'd as US2018/0037573 on 18- Feb-2018]	12-Oct-2017	CON of KP009; C/US3	US 10,059,693 on 28-Aug-2018	GRANTED
KP009; C/US6	16/043,000 (United States) [Pub'd as US2018/00327389 on 15-Nov-2018]	23-Jul-2018	CON of KP009; C/US5	US 10,316,022 on 11-Jun-2019	GRANTED
KP009; C/US7	16/043,007 (United States) [Pub'd as US2018/00327390 on 15-Nov-2018]	26-Jul-2018	CON of KP009; C/US5	US 10,329,280 on 25-Jun-2019	GRANTED
KP009; C/US8	16/400,672 (United States) [Pub'd as US2019/0284172 on 19-Sep-2019]	01-May-2019	CON of KP009; C/US7	US 10,723,719 on 28-Jul-2020	GRANTED
KP009; C/US9	16/900,657 (United States) [Pub'd as US2020/0299272 on 24-Sep-2020]	12-Jun-2020	CON of KP009; C/US8	US 11,352,343 on 07-Jun-2022	GRANTED
KP009; C/AU	2014/278231 (Australia) [Pub'd as AU2014/278231 on 24- Dec-2015]	11-Jun-2014	Nat'l Stage of KP009; C/MO	AU2014/278231 on 7-Sep-2017	GRANTED
KP009; C/AU2	2017/219063 (Australia) [Pub'd as AU2017/219063 on 14- Sep-2017]	24-Aug-2017	DIV of KP009; C/AU	AU2017/219063 on 15-Apr-2021	GRANTED
KP009; C/JP	2016-519614 (Japan)	11-Jun-2014	Nat'l Stage of KP009; C/MO	JP6469661 on 25-Jan-2019	GRANTED

	[Pub'd as JP2016534030 on 04-Nov-2016]				
KP009;C/JP3	2020-090240 (Japan)	11-Jun-2014	DIV of KP009;C/JP2	JP7058885 on 15-Apr-2022	GRANTED
KP009;C/JP4	2022-063260 (Japan)	11-Jun-2014	DIV of KP009;C/JP3		PENDING

PATENT FAMILY KP011					
TITLE(S) (A/H/D): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF					
Assignee: Kala					
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP011;EUS	14/530,092 (United States) [Pub'd as US2015/0125535 on 7-May-2015]	31-Oct-2014	US ORD of Provisionals 1, 3 & 5	US 9,458,169 on 4-Oct-2016	GRANTED
KP011;EUS2	14/981,105 (United States) [Pub'd as US2016/0115176 on 28-Apr-2016]	28-Dec-2015	DIV of KP011;EUS	US 9,790,232 on 17-Oct-2017	GRANTED
KP011;EUS3	15/712,645 (United States) [Pub'd as US2018/000982 on 11-Jan-2018]	22-Sep-2017	CON of KP011;EUS2	US 10,160,765 on 25-Dec-2018	GRANTED
KP011;EUS4	16/184,760 (United States) [Pub'd as US2019/0077810 on 14-Mar-2019]	08-Nov-2018	CON of KP011;EUS3	US 10,618,906 on 04-Apr-2020	GRANTED
KP011;EUS5	16/184,760 (United States) [Pub'd as US2020/0216459 on 09-Jul-2020]	02-Mar-2020	CON of KP011;EUS4	US 10,975,090 on 13-Apr-2021	GRANTED
KP011;EUS6	17/197,702 (United States) [Pub'd as US2021/0355133 on 18-Nov-2021]	10-Mar-2021	CON of KP011;EUS5		PENDING



KP011:EAU	2014/342042 (Australia) Pub'd as AU2014342042 on 12-May-2016	31-Oct-2014	National Stage of KP011:EMO	AU2014342042 on 30-Nov-2017	GRANTED
KP011:ECN	201480065624.X (China) [Pub'd as CN106061261 on 26-Oct-2016]	31-Oct-2014	National Stage of KP011:EMO	CN106061261 on 24-Apr-2018	GRANTED
KP011:EEP	14857737.2 (European Patent Office) [Pub'd as EP3062618 on 07-Sep-2016]	31-Oct-2014	National Stage of KP011:EMO	EP3062618 on 05-Feb-2020	GRANTED
KP011:EEP-DE	(Germany)		EP validation of KP011:EEP		GRANTED
KP011:EEP-FR	France		EP validation of KP011:EEP		GRANTED
KP011:EEP-GB	(Great Britain)		EP validation of KP011:EEP		GRANTED
KP011:EHK-EP	17102021.0 (Hong Kong) [Pub'd as HK1228197 on 03-Nov-2017]	31-Oct-2014	HK Registration of KP011:EMO	HK1228197 on 05-Feb-2021	GRANTED
KP011:EJP	2016-552255 (Japan) [Pub'd as JP2016535100] on 10-Nov-2016]	31-Oct-2014	National Stage of KP011:EMO	JP6426194 on 02-Nov-2018	GRANTED
KP011:EMX	MX/a/2016/005668 (Mexico) [Pub'd as MX2016005668 on 28-Oct-2016]	31-Oct-2014	National Stage of KP011:EMO	MX355330 on 16-Apr-2018	GRANTED
KP011:ENZ	719185 (New Zealand) [Pub'd as NZ719185 on 24-Nov-2017]	31-Oct-2014	National Stage of KP011:EMO	NZ719185 on 27-Feb-2018	GRANTED

**PATENT FAMILY: KP012**

TITLE(S) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Assignee: kaha

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP012.A/AU	2014/341966 (Australia) [Pub'd as AU2014341966 on 12-May-2016]	3-Nov-2014	Natl Stage of KP012.A/MO	AU2014341966 on 30-Nov-2017	GRANTED
KP012.A/JP	2016-552430 (Japan) [Pub'd as JP2016535779 on 17-Nov-2016]	3-Nov-2014	Natl Stage of KP012.A/MO	JP6426195 on 02-Nov-2018	GRANTED
KP012.A/US	15/032,595 (United States) [Pub'd as US2016/0257693 on 8-Sep-2016]	3-Nov-2014 (27-Apr-2016 (371 Date))	Natl Stage of KP012.A/MO	US 9,688,688 on 27-Jun-2017	GRANTED
KP012.A/US2	15/604,080 (United States) [Pub'd as US2017/0260193 on 14-Sep-2017]	24-May-2017	CON KP012.A/US	US 9,890,173 on 13-Feb-2018	GRANTED

PATENT FAMILY: KP013					
TITLE(S): CRYSTALLINE FORMS OF A THERAPEUTIC COMPOUND AND USES THEREOF					
Assignee: Kala					
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP013.B/US	15/529,969 (United States) [Pub'd as US 2017/0313724 on 2-Nov-2017]	25-May-2017	Natl Stage of KP013.B/MO	US 10,253,045 on 09-Apr-2019	GRANTED

PATENT FAMILY: KP014					
TITLE(S): A spec: UREA DERIVATIVE AND USES THEREOF; B spec: 1-AMINO-TRIAZOL(4,5-A)PYRIDINE SUBSTITUTE UREA DERIVATIVE AND USES THEREOF					
Assignee: Kala					
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP014.B/AU	2015-360,438 (Australia)	10-Dec-2015	Natl Stage of KP014.B/MO	AU2015360438 on 24-Jan-2019	GRANTED

TRADEMARK

REEL: 007935 FRAME: 0217

	[Pub'd as AU2015360438 on 15-Jun-2017]					
<b>KP014:BI/EP</b>	15814003.8 (European Patent Office) [Pub'd as EP3230272 on 18-Oct-2018] (Germany)	10-Dec-2015	Nat'l Stage of KP014:BMW	EP3230272 on 19-Aug-2020	GRANTED	
<b>KP014:BI/EP-DE</b>			Validation of EP3230272		GRANTED	
<b>KP014:BI/EP-FR</b>	(France)		Validation of EP3230272		GRANTED	
<b>KP014:BI/EP-GB</b>	(Great Britain)		Validation of EP3230272		GRANTED	
<b>KP014:BUS</b>	15/534,448 (United States) [Pub'd as US2018/0057489 on 01-Mar-2018]	8-Jun-2017	Nat'l Stage of KP014:BMW	US 10,174,022 on 08-Jan-2019	GRANTED	
<b>KP014:BUS2</b>	16/204,827 (United States) [Pub'd as US2019/0092772 on 28-Mar-2019]	29-Nov-2018	CON of KP014:BUS	US 10,875,857 on 29-12-2020	GRANTED	

<b>PATENT FAMILY: KP015</b>						
TITLE(S): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF						
Assignee: Kala						
<b>OUR REF. NO</b>	<b>APP. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY RELP</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>	
<b>KP015:AUS</b>	15/694,252 (United States) [Pub'd as US2018/0065977 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015:AUSPR	US 10,336,767 on 2-Jul-2019	GRANTED	

KP015,AUS2	16/4/15, 848 (United States) [Pub'd as US2019/0270752 on 05-Sep-2019]	17-May-2019	DIV of KP015,AUS	US 10,626,121 on 21-Apr-2020	GRANTED
KP015,AUS3	16/8/18, 033 (United States) [Pub'd as US2020/0216460 on 09-Jul-2020]	13-Mar-2020	CON of KP015,AUS2	US 11,104,685 on 31-Aug-2021	GRANTED
KP015,AUS5	17/5/54, 375 (United States) [Pub'd as US2022/0106326 on 07-Apr-2022]	17-Dec-2021	CON of KP015,AUS4		PENDING
KP015,AAU2	202017446 (Australia)	1-Sep-2017	DIV of KP015,AAU	AU202017446 on 08-Sept-2022	GRANTED
KP015,A/BR	BR112019004463.9 (Brazil)	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,A/CA	3036065 (Canada)	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,A/CN	201780055105.9 (China) [Pub'd as CN109688818 on 26- Apr-2019]	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,A/EP	17849362.3 (Europe) [Pub'd as EP3509421 on 17-Jul- 2019]	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,A/EP-HK	62019000441.1 (Hong Kong) [Pub'd as HK40040593 on 3-Jul- 2020]	26-Dec-2019	HK registration of KP015,A/EP		PENDING
KP015,A/KR	10-2019-7009753 (Korea)	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,A/NZ	751277 (New Zealand)	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING
KP015,B/US	15/694,331 (United States) [Pub'd as US2018/0065978 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015,B/USPR	US 10,253,036 on 09-Apr-2019	GRANTED

KP015:BUS2	15694,331 (United States) [Pub'd as US2019/0194218 on 27-Jun-2019]	26-Feb-2019	DIV of 15694,331	US11,021,487 on 01-Jun-2021	GRANTED
KP015:BUS3	17315,080 (United States) [Pub'd as US2021/0261562 on 26-Aug-2021]	07-May-2021	DIV of KP015:BUS2		PENDING
KP015:BAU	2017324713 (Australia)	1-Sep-2017	Nat'l phase of KP015:BMW	AU2017324713 on 26-Nov-2020	GRANTED
KP015:BEP	17849363,1 (Europe) [Pub'd as EP3509422 on 17-Jul-2019]	1-Sep-2017	Nat'l phase of KP015:BMW		PENDING
KP015:CUS	15694,383 (United States) [Pub'd as US2018/0065979 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015:CUSPR	US10,392,399 on 27-Aug-2019	GRANTED
KP015:CUS2	16513,505 (United States)[Pub'd as US2019/0337963 on 07-Nov-2019]	16-Jul-2019	DIV of KP015:CUS	US10,766,907 on 08-Sep-2020	GRANTED
KP015:CAU	2017324716 (Australia)	1-Sep-2017	Nat'l phase of KP015:CMO	AU2017324716 on 26-Nov-2020	GRANTED
KP015:CEP	17849365,6 (Europe) [Pub'd as EP3509423 on 17-Jul-2019]	1-Sep-2017	Nat'l phase of KP015:CMO		PENDING

<b>PATENT FAMILY: KP017</b>					
TITLE(S): BIOCHEMICAL BINDING OF RET9 AND VEGFR2 INHIBITORS					
Assignee: Kale					
<b>OUR REF NO</b>	<b>APPL NO &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO &amp; ISSUE DATE</b>	<b>STATUS</b>
KP017:BCA	3079673 (Canada)	19-Oct-2018	Nat'l phase of KP017:BMW		PENDING

KP017.B/CN	201860080672.4 (China) [Pub'd as CN11465601A on 28-Jul-2020]	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/EP	EP18801107.6 (Europe) [Pub'd as EP3697775 on 26-Aug-2020]	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/HK-CN	62021024397.3 (Hong Kong)	27-Jan-20121	HK of KP017.B/CN		PENDING
KP017.A/EP-HK	62021026025.8 (Hong Kong) [Pub'd as HK40036123 on 21-May-2021]	20-Feb-2021	HK of KP017.A/EP		PENDING
KP017.B/JP	(Japan) 2020-521977 (Japan)	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/KR	10-2020-7014314 (South Korea)	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/MX	Mx/a/2020/007183 (Mexico)	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/NZ	763580 (New Zealand)	19-Oct-2018	Nat'l phase of KP017.B/MO		PENDING
KP017.B/US	16/757_305 (United States) [Pub'd as US2021/0179582 on 17-Jun-2021]	17-Apr-2020	Nat'l phase of KP017.B/MO	US 11,401,260 on 02-Aug-2022	GRANTED
<b>PATENT FAMILY: KP019</b>					
<b>PATENT FAMILY: KP033</b>					
TITLE(S): Ocular Therapies					
Assignee: Kala					
<b>CUR. REF. NO.</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP033.A/USPR	63/298,931 (United States)	12-Jan-2022	Provisional		PENDING

<b>PATENT FAMILY: KP034</b>					
TITLE(S): Treatment of Neurovascular Diseases					
Assignee: Kalra					
<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP034.AUSPR	63/335,532 (United States)	27-Apr-2022	Provisional		PENDING

<b>PATENT FAMILY: KP035</b>					
TITLE(S): 1,2,4-Triazole/4,3-pyridine-5-yl Compounds Synthesis, and Uses Thereof					
Assignee: Kalra					
<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP035.AUSPR	63/298,9311 (United States)	22-Apr-2022	Provisional		PENDING

<b>PATENT FAMILY: KP036</b>					
TITLE(S): Indazole Compounds, Synthesis, and Uses Thereof					
Assignee: Kalra					
<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP036.AUSPR	63/337,813 (United States)	05-May-2022	Provisional		PENDING
<b>PATENT FAMILY: KP028</b>					
TITLE(S): Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome					
Assignee: Combarrio					
<b>OUR REF. NO</b>	<b>APPL. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP028/US	16/785,463 (United States) [Pub'd as US2020/03254524 on 15-Oct-2020]	7-Feb-2020	US ORD Filing of KP028/USPR1 & KP028/USPR2	US10,758,571 on 01-SEP-2020	GRANTED

KP028/US2	16/785,470 (United States) [Pub'd as US2020/0325452.4 on 15-Oct-2020]	7-Feb-2020	US ORD Filing of KP028/USPR1 & KP028/USPR2	US10,756,571 on 01-Sep-2020	GRANTED
KP028/US3	16/842,696 (United States) [Pub'd as US2020/0325452.4 on 15-Oct-2020]	7-Apr-2020	CON of KP08/US2		PENDING
KP028/US4	17/185,801 (United States) [Pub'd as US2021/0187034 on 24-Jun-2021]	25-Feb-2021	CON of KP089/US3 and CIP of US and US2	US11,129,953 on 28-Sep-2021	GRANTED
KP028/AU	2020270892 (Australia) [Pub'd as AU2020270892 on 02- Dec-2021]	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/BR	BR 112021020450-4 (Brazil) [Pub'd as BR112021020450 on 14-Dec-2021]	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/CA	3136614 (Canada) [Pub'd as CA3136614 on 5-Nov- 2021]	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/CL	202102655 (Chile)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/CN	202080041151.5 (China)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/EP	20788534.4 (Europe) [Pub'd as EP3952892 on 16- Feb-2022]	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/IN	202117051036 (India)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/JP	2021-560632 (Japan)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/KR	10-2021-7036569 (South Korea)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING



KP028/MX	MX/a/2021/012461 (Mexico)	7-Apr-2020	Natl Phase of KP028/WO		PENDING
KP028/NZ	781988 (New Zealand) [Pub'd as NZ781988 on 16-Feb-2022]	7-Apr-2020	Natl Phase of KP028/WO		PENDING

**PATENT FAMILY: KP029**  
 TITLE(S): Compositions Comprising Branched KGF-2-Derived Peptides and Methods For Use in Ocular Treatment  
 Assignee: Combargio

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP029/WO	PCT/US2022/021617 (PCT)	23-Mar-2022	PCT filing of KP029/USPR		PENDING

**PATENT FAMILY: KP030**  
 TITLE(S): Lyophilized Mesenchymal Stem Cell Derived Secretome and Uses Thereof  
 Assignee: Combargio

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP030/WO	PCT/US2021/026159 (PCT) [Pub'd as WO2021/207282 on 14-Oct-2021]	06-Apr-2021	PCT Filing of KP030/USPR		PENDING

KP030/US	17/224,068 (United States) [Pub'd as US20210369617 on 02-Dec-2021]	06-Apr-2021	US ORD Filing of KP030/USPR	PENDING
KP030/AU	2021251785 (Australia)	06-Apr-2021	Nat'l Phase of KP030/WO	PENDING
KP030/CN	(China)	06-Apr-2021	Nat'l Phase of KP030/WO	IN PROCESS
KP030/EP	217837/0.7 (Europe)	06-Apr-2021	Nat'l Phase of KP030/WO	PENDING
KP030/JP	2022-561111 (Japan)	06-Apr-2021	Nat'l Phase of KP030/WO	PENDING
KP030/KR	10-2022-7038878 (Korea)	06-Apr-2021	Nat'l Phase of KP030/WO	PENDING

TRADEMARK  
REEL: 007935 FRAME: 0225

<b>PATENT FAMILY: KP031</b>					
TITLE(S): Compositions Comprising C-Met Agonist Antibodies and Methods For Use in Ocular Treatment					
Assignee: Combangio					
<b>OUR REF. NO</b>	<b>APP. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>
KP031/WO	PCT/US2022/021618	23-Mar-2022	PCT Filing of KP031/USPR		PENDING

<b>PATENT FAMILY: KP032</b>					
TITLE(S): Processes For Making and Using a Cellular Fibronectin Composition					
Assignee: Combangio					
<b>OUR REF. NO</b>	<b>APP. NO. &amp; COUNTRY</b>	<b>FILING DATE</b>	<b>FAMILY REL'P</b>	<b>PATENT NO. &amp; ISSUE DATE</b>	<b>STATUS</b>

KP032IWO	PCT/US202236036 (PCT)	1-Jul-2022	PCT filing of KP032/USPR1 and USPR2	PENDING
KP032IUS1	17/856,944 (United States)	1-Jul-2022	US non-provisional of KP032/USPR1 and USPR2	PENDING
KP032IUS2	17/860,954 (United States)	8-Jul-2022		PENDING

**PATENT FAMILY: KP037**  
 TITLE(S): Methods and Assays for Secretome Activity Analysis  
 Assignee: Combangio

OUR REF. NO	APP. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP037/USPR1	63/359,743 (United States)	8-Jul-2022	Provisional		PENDING

**PATENT FAMILY: KP038**  
 TITLE(S): Preparation and Purification Methods for Mesenchymal Stem Cell Derived Secretome  
 Assignee: Combangio

OUR REF. NO	APP. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP038/USPR1	63/404,455 (United States)	07-Sept-2022	Provisional		PENDING



EXHIBIT B

Trademarks

OVER REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM001/US (United States)	85/932,177	14-May-2013	42	4,585,580	12-Aug-14	REGISTERED

**KALA** **KTMM001** **TYPE:** SERVICE MARK **MARK:**  
**FAMILY:**  
**DESCRIPTION:** Research and development services and technical consultation relating to the development and scientific testing of pharmaceuticals and drug formulation technology

OVER REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM002/US (United States)	85/932,175	14-May-2013	005	5,401,810	13-Feb-18	REGISTERED

**KALA** **KTMM002** **TYPE:** TRADEMARK (character mark) **MARK:** **KALA**  
**FAMILY:**  
**DESCRIPTION:** As amended 12/5/17: Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a wide range of pharmaceuticals

OVER REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM004/CA (Canada)	1873400	15-Dec-2017	N/A	TMA1,085,451	20-Oct-20	REGISTERED
KTM004/EUTM (European Union)	017604083	15-Dec-2017	005	017604083	2-May-18	REGISTERED
KTM004/Brexit (UK)	UK00917604083	15-Dec-2017	005	UK00917604083	2-May-18	REGISTERED
KTM004/MX (Mexico)	1986902	15-Dec-2017	005	1860087	15-Dec-17	REGISTERED

**KALA** **KTMM004** **TYPE:** TRADEMARK (character mark) **MARK:** **VYSTALI**  
**FAMILY:**  
**DESCRIPTION:** Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye

Kala Pharmaceuticals, Inc. Confidential 1/12

KALA FAMILY:		KT/M005 TYPE:		TRADEMARK (character mark)		MARK:		LORPREXIO	
DESCRIPTION:		Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye							
GR/REF. NO	APPL. NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS			
KT/M005/CA (Canada)	1873388	15-Dec-2017	N/A	TMA1,066,019	11-Dec-19	REGISTERED			
KT/M005/E/TM (European Union)	017604067	15-Dec-2017	005	017604067	2-May-18	REGISTERED			
KT/M005/Brexit (UK)	UK00917604067	15-Dec-2017	005	UK00917604067	2-May-18	REGISTERED			
KT/M005/MX (Mexico)	1986896	15-Dec-2017	005	1860085	15-Dec-17	REGISTERED			

KALA FAMILY:		KT/M007 TYPE:		TRADEMARK (character mark)		MARK:		VISOVA	
DESCRIPTION:		Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye							
GR/REF. NO	APPL. NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS			
KT/M007/CA (Canada)	1873393	15-Dec-2017	005	TMA1,066,022	11-Dec-19	REGISTERED			
KT/M007/E/TM (European Union)	017604059	15-Dec-2017	005	017604059	2-May-2018	REGISTERED			
KT/M007/Brexit (UK)	UK00917604059	15-Dec-2017	005	UK00917604059	2-May-2018	REGISTERED			
KT/M007/MX (Mexico)	1986899	15-Dec-2017	005	1860086	15-Dec-2017	REGISTERED			

Kala Pharmaceuticals, Inc.

Confidential

2/12

<b>KALA</b>	<b>KTMM009</b>	<b>TYPE:</b>	<b>TRADEMARK</b> (character mark)	<b>MARK:</b>	<b>ZUDREYA</b>
<b>FAMILY:</b>					
<b>DESCRIPTION:</b>	Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders: ophthalmic pharmaceutical preparations				
<b>OR. REF. NO.</b>	<b>APP. N. NO.</b>	<b>FILING DATE</b>	<b>INT'L. CLASS.</b>	<b>REGISTRATION NO.</b>	<b>REGISTRATION DATE</b>
<b>KTMM009/US2</b> (United States)	90/749,282	02-Jun-2021	005		
					<b>STATUS</b>
					PENDING/ TO ABANDON

Kala Pharmaceuticals, Inc.

Confidential

3/12

50574817.1

ACTIVEUS 197374026v. 2

TRADEMARK

REEL: 007935 FRAME: 0231

RECORDED: 12/22/2022